Seelos Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1994
Net Income	-27.12	-37.88	-73.53	-66.05	-19.1	-51.26	Upgrade
Depreciation & Amortization	0.06	0.06	0.05	0	0	0	Upgrade
Share-Based Compensation	3.88	3.99	5.07	8.35	2.04	0.46	Upgrade
Other Operating Activities	4.97	9.93	6.8	8.71	-3.86	31.49	Upgrade
Operating Cash Flow	-18.21	-23.91	-61.6	-49	-20.91	-19.31	Upgrade
Share Issuance / Repurchase	12.34	19.02	0.56	105.42	15.26	29.52	Upgrade
Debt Issued / Paid	-7.67	-7.64	-1.89	6.65	11.05	0	Upgrade
Other Financing Activities	-	-	-0.27	-	-	-	Upgrade
Financing Cash Flow	4.67	11.38	-1.6	112.07	26.31	29.52	Upgrade
Net Cash Flow	-13.54	-12.54	-63.2	63.07	5.4	10.22	Upgrade
Free Cash Flow	-18.21	-23.91	-61.6	-49	-20.91	-19.31	Upgrade
Free Cash Flow Margin	-922.29%	-1085.43%	-	-	-	-5148.00%	Upgrade
Free Cash Flow Per Share	-11.20	-39.04	-139.00	-129.37	-112.12	-228.14	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).